Eyer, L.Nencka, R.Huvarová, I.Palus, M.Alves, M.J.Gould, E.A.De Clercq, E.Rusek, D.2017-02-212017-02-212016-09-01J Infect Dis. 2016 Sep 1;214(5):707-11. doi: 10.1093/infdis/jiw226. Epub 2016 May 270022-1899http://hdl.handle.net/10400.18/4303There is growing evidence that Zika virus (ZIKV) can cause devastating infant brain defects and other neurological disorders in humans. However, no specific antiviral therapy is available at present. We tested a series of 2'-C- or 2'-O-methyl-substituted nucleosides, 2'-C-fluoro-2'-C-methyl-substituted nucleosides, 3'-O-methyl-substituted nucleosides, 3'-deoxynucleosides, derivatives with 4'-C-azido substitution, heterobase-modified nucleosides, and neplanocins for their ability to inhibit ZIKV replication in cell culture. Antiviral activity was identified when 2'-C-methylated nucleosides were tested, suggesting that these compounds might represent promising lead candidates for further development of specific antivirals against ZIKV.engZika VirusFlavivirusNucleoside AnalogueAntiviralTherapyInfecções Sistémicas e Zoonosesjournal article10.1093/infdis/jiw226